Investing.com — Compass Pathways Plc (NASDAQ: CMPS )股价已达到新的52周低点，触及3.15美元，较其52周高点10.31美元大幅下跌70%。这一最新价格标志着该专注于心理健康创新疗法（包括迷幻药治疗）的公司出现显著下滑。根据 InvestingPro ...

The results of COMP004 build upon previous findings from the Phase 2b trial COMP001, which showed that a single 25mg dose of COMP360 psilocybin was associated with a rapid and highly statistically ...

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Seven ...

CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, 2025, 8:00 a.m. ET ...

In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

LONDON & NEW YORK, March 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the ...

Ladies and gentleman thank you for standing by, and welcome to the COMPASS Pathways' Ltd. Fourth Quarter 2024 Investor Call. [Operator Instructions] I would now hand today’s call over to Steve ...